HomeQuestion

Since the approval of Carbo/VP-16/Atezolizumab (IMpower133) for extensive stage small cell lung cancer, how are you treating those patients who progress > 6 months after chemotherapy alone who were treated prior to the approval of IMpower133?

1 Answers

Mednet Member

Medical Oncology · UCSD Moores Cancer Center

2nd line anti-PD1 (+/- anti-CTLA4) is reasonable for patients who did not receive atezo in the 1st line setting.